The signed agreement between BioDelivery Sciences International, Inc. (NASDAQ:BDSI) and a managed care provider will make the access to BUNAVAIL (buprenorphine and naloxone) buccal film (CIII) much easier. However, there are not details about the agreement whose managed care plan which officially goes into effect on January 1, 2017. The agreement would provide a formulary position of gaining access to BUNAVAIL against its current non-formulary position. Nonetheless, there are speculations by BDSI that health care providers may go ahead of the stipulated effective date.

The strategy for BUNAVAIL

Listening to him speak about the agreement, Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI sound enthusiastic to what he referrers to as a 20106 strategy. He is optimistic of a successful implementation of the agreement which is expected to bring in a tremendous opportunity for transition to growth. The company’s mission has been to streamline its commercial efforts which will in return create efficiencies geared towards prevention if burning of cash.

 Sirgo goes ahead to observe the company’s progress in being able to manage care contracts that have increased global availability of BUNAVAIL as well profitable  BUNAVAIL operations. The two are critical endeavors which could significantly benefit from the recent agreement. After all, the entire managed care plan takes care of many lives with an increased volume of prescriptions for buprenorphine products for opioid dependence.

About BDSI and the promising take ahead

The agreement is all about a significant milestone for the two; BUNAVAIL and BDSI. They are both raring to go given the promising market but not at the expense of quality. Sirgo confirms that the company is in continue pursuit of any promising opportunity given that many more people are showing interest in the benefits of BUNAVAIL.

A word of caution about this prescription is that its use requires bits and pieces of counseling and psychosocial support to anyone who wants to achieve a complete treatment plan.